bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract P2-13-20: Randomized clinical trial comparing 2-octylcyanoacrylate versus intradermic suture with nylon: Similar cosmetic results with different safety profile
Authors: Freitas-Junior Ruffo , Becker Thiago S , Rahal Rosemar MS , Paulinelli Regis R 
Published: May 2015

Abstract
Introduction: There are multiple options available for closing surgical incisions. This study compared the cosmetic results between the use of 2-octylcyanoacrylate and nylon sutures in elective breast surgery. Objectives: To compare the efficacy and cosmetic outcome between the adhesive and conventional suturing with nylon on the cutaneous synthesis mammary surgeries. Methods: we performed a prospective, randomized, controlled trial with 79 patients, 37 in group 2-octylcyanoacrilate and 42 in the group with nylon suture. We evaluated the surgical aspect of the scar in 40 and 180 days, the occurrence of complications (such as dehiscence, hematoma, infection and allergic reactions), the size of the wound and breast lesions, surgical time and skin closure time, hemoglobin and preoperative WBC, age, height and weight of patients. Statistical analysis was performed by t test and chi-square. Results and discussion: the study was stopped before the end of the recruitment of patients for the presence of a greater number of dehiscence in the adhesive group (OR: 11.42, 95% CI 1.36 - 96.02, p=0.007). There were no significant differences between the groups regarding other complications, not in relation to surgical time and the aesthetic appearance of scars after 40 and 180 days. The average size of the wound was greater in the adhesive group than in the suture, being respectively 32.97 (+ 10.54) mm and 27.64 (+ 9.56) mm, no correlation of size with the largest number of dehiscence. Conclusion: The results showed that the cosmetic scar appearance of 2-octylcyanoacrilate is equivalent to those obtained with the intradermal nylon suture, but the risk of dehiscence is higher.
Citation Format: Ruffo Freitas-Junior, Thiago S Becker, Rosemar MS Rahal, Regis R Paulinelli. Randomized clinical trial comparing 2-octylcyanoacrylate versus intradermic suture with nylon: Similar cosmetic results with different safety profile [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P2-13-20.
Abstract P2-13-23: The oncologic safety of nipple-areolar complex skin sparing mastectomy compared with skin sparing mastectomy: 8 years follow up results
Authors: Yeu Kyung Jun , Park Jeong Yeong , Choi Jung Eun , Kang Su Hwan , Bae Young Kyung , Lee Soo Jung 
Published: May 2015

Abstract
Background: Skin sparing mastectomy (SSM) has been conducted in breast cancer patient because of both oncologic safety and cosmetic satisfaction. Preservation of nipple-areolar complex (NAC) is helpful to keep more natural breast shape, but, can cause anxiety about local recurrence. This study reviewed long term follow-up result of SSM and nipple-areolar skin sparing mastectomy (NASSM), retrospectively.
Patients and methods: This study included 272 primary breast cancer patients who received SSM (94 patients) or NASSM (178 patients) except bilateral breast cancer from September 1996 to December 2008. Frozen section was conducted for analysis of NAC resection margin status. In case of positive resection margin, NAC was sacrificed. Local recurrence and overall survival of SSM and NASSM group was analyzed.
Results: The mean follow-up was 94.9 months. 81 NAC resection margins (29.8%) were invaded by tumor cells. The positive resection margin of NAC was associated with presence of ductal carcinoma in situ (p=0.005), especially extensive intraductal component (p=0.005) and invasive carcinoma with multiplicity (p=0.048). The patients in NASSM group tended to have more worse disease free survival than those in SSM group (75.3% vs 86.2%, P=0.087). But, in analysis of only local recurrence including NAC, there were 25 cases (14.0%, 7 in skin flap and 18 in NAC) of local recurrence in NASSM group and 8 (8.5%) in SSM group. Local recurrence free survival of the NASSM group was 86.0% and that of the SSM group was 91.5% (P=0.278). Distant recurrence after surgical treatment for local relapse occurred in only one SSM case. There was no significant difference for the overall survival between NASSM and SSM group (97.8% vs 96.8%, p=0.556).
Conclusion: In this study, result of long term follow up showed that patients in NASSM group tend to have more local recurrence than patients in SSM group, even if there is no statistically significance. However, surgically well-controlled local recurrence of skin flap and/or NAC did not affect on overall survival. NASSM is alternative method for SSM with oncological safety and better cosmetic outcome.
Citation Format: Kyung Jun Yeu, Jeong Yeong Park, Jung Eun Choi, Su Hwan Kang, Young Kyung Bae, Soo Jung Lee. The oncologic safety of nipple-areolar complex skin sparing mastectomy compared with skin sparing mastectomy: 8 years follow up results [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P2-13-23.
Abstract P2-16-03: C-Met is a potential therapeutic target for antibody-drug conjugates in breast cancer
Authors: Fu Yanwen , Gros Edwige , Lee Alice , Johnson Kimberly , Zhang Hong , Yalamanchili Silpa , Motamed Kouros , Chen Gary , Jones Bryan , Miao David , Kaufmann Gunnar F 
Published: May 2015

Abstract
C-Met, a transmembrane receptor tyrosine kinase, plays a key role in malignant transformation of epithelial cells by activating signal transduction pathways essential for cellular proliferation, survival, migration and invasion. C-Met overexpression, with or without gene amplification, has been reported in primary breast cancers and correlate with poor prognosis. C-Met signaling inhibition, such as tyrosine kinase inhibitors (TKIs), usually not sufficient for sustained treatment efficacy, we believe that antibody drug conjugates (ADCs) offer the promise and potential of delivering potent anti tumor activity with the advantage of reduced side effects. We generated antibody drug conjugates containing a proprietary human anti-c-Met antibody (STI-D0606) with either a tubulin inhibitor or DNA damaging agent, such as doxorubicin analogs. STI-D0606, a fully human antibody (IgG1) selected from phage library was conjugated with the cytotoxin via site specific bioconjugation. The conjugates retained binding affinity and showed potent cell killing in a variety of c-Met positive cell lines. Progress will be reported in terms of in vivo efficacy in c-Met-positive human breast tumor xenograft in preclinical models.
Citation Format: Yanwen Fu, Edwige Gros, Alice Lee, Kimberly Johnson, Hong Zhang, Silpa Yalamanchili, Kouros Motamed, Gary Chen, Bryan Jones, David Miao, Gunnar F Kaufmann. C-Met is a potential therapeutic target for antibody-drug conjugates in breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P2-16-03.
Abstract P3-05-14: Modeling chemoendocrine therapy for ER+/p53wt luminal breast cancer
Authors: Cao Shiliang A , Lim Elgene , Brown Myles , Bailey Shannon T 
Published: May 2015

Abstract
Background
ER+ breast cancers are predominantly p53 wildtype (wt). Despite this genotype, these cancers are relatively resistant to chemotherapy-induced apoptosis in the presence of estrogen. Thus, current clinical practice is to administer hormonal therapy and chemotherapy sequentially rather than concurrently. Using the ER+/p53wt cell line MCF-7, we previously demonstrated that ER bound by either the ER agonist estradiol or partial antagonist tamoxifen inhibits the expression of a set of proapoptotic p53 target genes, whereas the full ER antagonist fulvestrant, a selective ER downregulator (SERD), removes the ER-mediated suppression of these genes, sensitizing breast cancer cells to p53-mediated cell death .We hypothesize that effective chemoendocrine therapy requires complete ER antagonism resulting in ER downregulation, increased p53 activity, and ultimately apoptosis.
Methods:
To model mechanisms of tumor sensitivity and resistance to therapy in vivo, therapeutic experiments were performed in immunodeficient mice bearing ER+/p53wt tumor xenografts derived from a 61-year-old African-American female with grade 2 invasive ductal carcinoma. The mice were randomly assigned to the following treatment groups: A) fulvestrant B) tamoxifen, C) doxorubicin, D) fulvestrant plus doxorubicin, E) tamoxifen plus doxorubicin, and F) control. Tumors were measured weekly for 42 days to determine treatment effects on growth. In addition, RNA was harvested from tumors at an early time point for RNA sequencing to determine genes regulated by the treatments.
Results:
Combination therapy comprising doxorubicin plus fulvestrant resulted in tumor regression compared with single-agent or doxorubicin plus tamoxifen treatment, which inhibited the growth of tumors but did not lead to their regression.
Conclusions:
Current paradigms for the treatment of ER+ breast cancer either in the adjuvant or advanced setting have involved the sequential use of endocrine therapy and chemotherapy. This protocol is partially based on evidence of potential antagonism between tamoxifen and chemotherapy as observed in early studies. Our published work in vitro and the preclinical study presented here suggest that complete ER antagonism with SERDs such as fulvestrant is required to overcome the ability of ER to block p53-mediated apoptosis. Our results suggest treatments involving fulvestrant concurrent with chemotherapies involving p53 activation should be considered for the treatment of patients with ER+/p53wt breast cancer.
Citation Format: Shiliang A Cao, Elgene Lim, Myles Brown, Shannon T Bailey. Modeling chemoendocrine therapy for ER+/p53wt luminal breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P3-05-14.
Abstract P3-07-27: Patterns of chemotherapy (CT) use by molecularly-defined subtype among a population-based cohort of breast cancer (BC) patients (pts) from California
Authors: Clarke Christina A , Chu Laura , Wang Lisa , Song Chunyan , Green Marjorie , Moy Lisa , Yang Juan , Tao Li , Gomez Scarlett Lin 
Published: May 2015

Abstract
Background: Guidelines describe recommended BC treatments (tx) according to tumor subtype; however, population-based data regarding tx utilization are limited.
Objective: To describe tx utilization by tumor HER2, hormone receptor (HR) status, and stage among representative pts from California.
Methods: We examined patterns of CT (including biologic tx) reported as received for all 131,450 female BC pts diagnosed with primary invasive BC in California between 1/1/2005 and 12/31/2011 in the California Cancer Registry, including n=19,918 HER2+ [65% HR+, 33% HR-]; n=91,919 HER2- [84% HR+, 15% HR-]; and n=19,613 HER2 unknown. Neoadjuvant & adjuvant CT data was only available for a subset of 35,040 pts diagnosed 2010-2011 (4,609 HER+; 27, 604 HER2-). Descriptive statistics were used for comparisons.
Results: CT was reported as highest among pts with metastatic breast cancer (MBC) and HER2+ status (Table 1). The proportion of pts with early BC (EBC) receiving CT increased from 58% in 2005 to 69% in 2010, but was generally steady for MBC pts (74.2% in 2005 to 79.6% in 2011). 20.7% of HER2+ pts received neoadjuvant CT vs 8.6% for HER2- pts. Similarly, adjuvant CT was more common in HER2+ (55.5%) than HER2- (28.5%) pts. As expected the proportion of pts receiving CT was lower in HR+ vs HR- pts for EBC and MBC [eg. all stages HER2+ (62% vs 71%); HER2- (33% vs 68%)].
Conclusion: In this population-based cohort, ∼20-40% of MBC pts may not have received any CT or biologics. CT was more commonly received by HER2+ patients compared to HER2- patients for both EBC and MBC.
Table 1. Patterns of chemotherapy (including biologics) use among California female BC pts by stage and HER2 status, 2005-2011EBCMBCHER2+HER2-HER2+HER2-Any chemotherapyNo5898 (33.4%)52467 (61.0%)317 (22.6%)1519 (43.7%)Yes11463 (64.8%)32403 (37.7%)1063 (75.9%)1894 (54.5%)Unknown322 (1.8%)1128 (1.3%)20 (1.4%)60 (1.7%)Any neoadjuvant therapy (2010-2011 data only)No3546 (76.9%)24794 (89.8%)**Yes953 (20.7%)2381 (8.6%)**Unknown110 (2.4%)429 (1.6%)**Any adjuvant therapy (2010-2011 data only)No1943 (42.2%)19296 (69.9%)**Yes2556 (55.5%)7879 (28.5%)**Unknown110 (2.4%)429 (1.6%)*** not applicable
Citation Format: Christina A Clarke, Laura Chu, Lisa Wang, Chunyan Song, Marjorie Green, Lisa Moy, Juan Yang, Li Tao, Scarlett Lin Gomez. Patterns of chemotherapy (CT) use by molecularly-defined subtype among a population-based cohort of breast cancer (BC) patients (pts) from California [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P3-07-27.
Abstract P3-07-34: Breast cancer pathologic subtype and fetal microchimerism
Authors: Mahoney David A , Winget Veronica L , Gadi VK , Li Christopher I , Porter Peggy L , McDougall Jean A 
Published: May 2015

Abstract
Background: Stably persistent offspring-origin cells in a woman’s circulation and tissues decades after pregnancy, also known as fetal microchimerism, is deficient in women with biologically unselected breast cancer and suggests a protective role. Although the finding is in harmony with the well-known association of parity with protection against future breast cancer, it has recently emerged that certain tumor types such as triple negative breast cancer are positively associated with parity. Here we tested the hypothesis that fetal microchimerism is positively associated with triple negative breast cancer in young women.
Methods: Buffy coat specimens were obtained from a subset (n=450) of pathologically confirmed low-risk luminal and high-risk triple negative breast cancer patients and control participants from a population-based cohort study of all women aged 20-44 diagnosed with invasive breast cancer in the three county Seattle-Puget Sound metropolitan area from 2004-2010. Using quantitative PCR, DNA extracts from these specimens were tested for the presence and concentration of Y chromosome sequence DYS14, a marker of male fetal microchimerism.
Results: At this interim analysis of 405 specimens, 29.3% (56/191) of the healthy controls tested positive. Using controls as a reference group, 37.8% (34/90; OR .68; 95% CI .39-1.2) of women who developed luminal breast cancer tested positive for the presence of DYS14, while 26.6% (33/124; OR 1.14; 95% CI .67-1.96) of women who developed triple negative breast cancer tested positive.
Discussion: A preliminary analysis does not suggest an association between fetal microchimerism and breast cancer pathologic subtype in young women. Additional analyses are pending and will be presented at the meeting. Young women may regulate fetal microchimerism differently and surprisingly our data may suggest that as fetal microchimerism emerges later in life in the circulation, so does the protection against breast cancer – a finding consistent with population based studies of parity as a risk factor for breast cancer.
Citation Format: David A Mahoney, Veronica L Winget, VK Gadi, Christopher I Li, Peggy L Porter, Jean A McDougall. Breast cancer pathologic subtype and fetal microchimerism [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P3-07-34.
Abstract P3-11-10: Response to subsequent therapies after failure to achieve pathologic complete response (pCR) after neo-adjuvant chemotherapy (NAC) in patients (pts) with triple negative breast cancer (TNBC)
Authors: Pahuja Shalu , McGuire Kandace , Davidson Nancy , Brufsky Adam , Rastogi Priya , Jankowitz Rachel , Lembersky Barry , Puhalla Shannon 
Published: May 2015

Abstract
Background: More than half of pts with TNBC do not achieve a pCR after NAC, which carries a poor prognosis. It is unclear whether these patients respond to subsequent therapies on relapse. We sought to determine the time to progression (TTP) on subsequent therapies for recurrent disease in TNBC patients who did not achieve pCR to neo-adjuvant therapy.
Methods: We retrospectively identified 117 TNBC pts who received NAC from 2009 through 2012 using an electronic database at the Magee Women’s Breast Cancer Program at the University of Pittsburgh. Patient records were then assessed for pts who did not achieve a pCR for time to local or distant recurrence (TTR) and time to progression (TTP) on susbequent therapies.
Results: 86 of 117 TNBC pts did not achieve pCR to NAC defined as residual disease present in either the breast and/or axilla. Median follow up was 2 yrs (range 1-4yrs). Out of these 86 pts, 21 pts(25%) had recurrence in form of distant metastasis or local recurrence. Nearly all pts(95%) received anthracycline and taxane based NAC. Median TTR was 19 months (4-29 months). Therapies received in the metastatic setting most commonly included single agent capecitabine, paclitaxel, nab-paclitaxel, and eribulin. The most commonly received doublets included carboplatin with paclitaxel or gemcitabine. Median TTP on systemic chemotherapy was 15 weeks (3 -39 weeks), 6 weeks (1-24 weeks) and 6 weeks (2-9 weeks) in first, second and third line setting, respectively. Greater than 80% pts were able to receive two lines of systemic chemotherapy but &lt;50% received third line treatment. Two pts died before initiating any systemic treatment.
Conclusions: Response to subsequent chemotherapeutic regimens in metastatic setting in TNBC pts who do not achieve pCR to anthracycline and taxane based NAC is limited. This highlights the importance of identifying new agents and targeted therapies for this poor prognosis sub-type.
Citation Format: Shalu Pahuja, Kandace McGuire, Nancy Davidson, Adam Brufsky, Priya Rastogi, Rachel Jankowitz, Barry Lembersky, Shannon Puhalla. Response to subsequent therapies after failure to achieve pathologic complete response (pCR) after neo-adjuvant chemotherapy (NAC) in patients (pts) with triple negative breast cancer (TNBC) [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P3-11-10.
Abstract P3-11-15: Different clinical usefulness of AJCC response criteria according to the subtypes in stage II/III breast cancer patients after neoadjuvant chemotherapy
Authors: Yang Yaewon , Im Seock-Ah , Kim Tae-Yong , Lee Kyung-Hun , Keam Bhumsuk , Han Sae-Won , Oh Do-Youn , Kim Tae-You , Han Wonshik , Moon Hyeong-Gon , Park In Ae , Noh Dong-Young 
Published: May 2015

Abstract
Background: Response to neoadjuvant chemotherapy (NAC) is a useful prognostic marker for relapse and overall survival but their prognostic role is distinct in different breast cancer subtypes. Pathologic complete response (pCR) is a current gold standard for evaluating response to NAC. Despite its clinical usefulness, discrimination into pCR and non-pCR is too simple because non-pCR includes broad range of actual responses from very good partial response to even progressive disease. American Joint Committee on Cancer (AJCC) 7th edition proposed response criteria for NAC based on precise clinical stage before NAC and pathologic staging after NAC. The purpose of this study is to evaluate the clinical usefulness of AJCC response criteria in each breast cancer subtypes.
Patients and Methods: Patients with clinical stage II or III breast cancer treated with NAC at Seoul National University Hospital were enrolled and reviewed retrospectively. AJCC response criteria for NAC were adopted from the AJCC 7th edition: complete response (CR), absence of invasive carcinoma in both breast and lymph node; partial response (PR), decrease in either or both T or N stage; no response (NR), no change or increase in either or both T or N stage. The definition of each breast cancer subtypes were adopted from 2011 St Gallen Consensus Panel for current study.
Results: From January 2009 to December 2010, 183 patients were enrolled in the study with median follow up period of 38.0 months. AJCC response was significantly associated with relapse free survival (RFS) (P&lt;0.001), whereas pCR was not (P=0.120). In subgroup analysis, AJCC response was a significant prognostic factor for RFS in luminal B (P&lt;0.001), HER-2 enriched (P=0.035) and triple negative breast cancer (P=0.037) groups, but not in luminal A group patients (P=0.101). On the contrary, pCR was not significantly associated with RFS in any groups.
Conclusion : AJCC criteria is an easily reproducible tool for response evaluation for breast cancer patients in NAC setting compared with classically used pCR in all breast cancer subgroups except luminal A.
Citation Format: Yaewon Yang, Seock-Ah Im, Tae-Yong Kim, Kyung-Hun Lee, Bhumsuk Keam, Sae-Won Han, Do-Youn Oh, Tae-You Kim, Wonshik Han, Hyeong-Gon Moon, In Ae Park, Dong-Young Noh. Different clinical usefulness of AJCC response criteria according to the subtypes in stage II/III breast cancer patients after neoadjuvant chemotherapy [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P3-11-15.